Condition: Primary Immune Thrombocytopenia (ITP) · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
This prospective, multicenter, randomized study aim to evaluate the efficacy and safety of romiplostim N01 combined with glucocorticoids as the first-line treatment for newly diagnosed adult primary immune thrombocytopenia (ITP).
This description comes directly from the study's public registry record.
Lei Zhang · +8613502118379 · zhanglei1@ihcams.ac.cn
Yunfei Chen · +8618502220788 · chenyunfei@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Chinese Academy of Medical Science and Blood Disease Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06992128